|May 20, 2020
JAMA Study Shows No Benefit from Hydroxychloroquine for Covid-19
The study was conducted by researchers at New York-Presbyterian Hospital—Columbia University Irving Medical Center, and published last week in the New England Journal of Medicine (JAMA). It showed that among patients hospitalized with COVID-19, treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality. The observational study included 1,376 patients. There continue to be, however, numerous randomized, controlled trials of hydroxychloroquine underway.
The Federal & Drug Administration has granted Emergency Use Authorization (EUA) for Chloroquine Phosphate and Hydroxychloroquine Sulfate for Certain Hospitalized COVID-19 Patients but cautioned against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. The agency stresses that use under the EUA are for a certain population of hospitalized patients with COVID-19. Given the uncertainty regarding the potential benefits and risks for COVID-19, it is critical to first have evidence from clinical trials.< Previous Article | Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'firstname.lastname@example.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©